133 related articles for article (PubMed ID: 2105541)
1. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P
Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541
[TBL] [Abstract][Full Text] [Related]
2. Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
Herman EH; Ferrans VJ; Bhat HB; Witiak DT
Cancer Chemother Pharmacol; 1987; 19(4):277-81. PubMed ID: 3594714
[TBL] [Abstract][Full Text] [Related]
3. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase].
Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P
G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445
[TBL] [Abstract][Full Text] [Related]
4. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
[TBL] [Abstract][Full Text] [Related]
5. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione.
Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P
Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
Herman EH; el-Hage A; Ferrans VJ
Toxicol Appl Pharmacol; 1988 Jan; 92(1):42-53. PubMed ID: 3124293
[TBL] [Abstract][Full Text] [Related]
7. [The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin].
Villani F; Galimberti M; Poggi P; Rozza A; Lanza E; Favalli L; Scavini C
Cardiologia; 1992 Oct; 37(10):709-11. PubMed ID: 1296877
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Drugs Exp Clin Res; 1988; 14(9):563-70. PubMed ID: 3147886
[TBL] [Abstract][Full Text] [Related]
9. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine.
Herman EH; Ferrans VJ
Lab Invest; 1983 Jul; 49(1):69-77. PubMed ID: 6408310
[TBL] [Abstract][Full Text] [Related]
10. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds.
Herman EH; Ferrans VJ
Cancer Treat Rev; 1987 Dec; 14(3-4):225-9. PubMed ID: 3125968
[No Abstract] [Full Text] [Related]
13. Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles.
Herman EH; Ferrans VJ; Myers CE; Van Vleet JF
Cancer Res; 1985 Jan; 45(1):276-81. PubMed ID: 3917371
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
[TBL] [Abstract][Full Text] [Related]
15. Effect of trimetazidine on early and delayed doxorubicin myocardial toxicity.
Perletti G; Monti E; Paracchini L; Piccinini F
Arch Int Pharmacodyn Ther; 1989; 302():280-9. PubMed ID: 2636823
[TBL] [Abstract][Full Text] [Related]
16. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
Shipp NG; Dorr RT; Alberts DS; Dawson BV; Hendrix M
Cancer Res; 1993 Feb; 53(3):550-6. PubMed ID: 8425187
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
Zhang J; Herman EH; Ferrans VJ
Am J Pathol; 1993 Jun; 142(6):1916-26. PubMed ID: 8506959
[TBL] [Abstract][Full Text] [Related]
18. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
19. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs.
Herman EH; Ferrans VJ; Young RS; Hamlin RL
Cancer Res; 1988 Dec; 48(23):6918-25. PubMed ID: 3141049
[TBL] [Abstract][Full Text] [Related]
20. Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).
Chakrabarti KB; Hopewell JW; Wilding D; Plowman PN
Eur J Cancer; 2001 Jul; 37(11):1435-42. PubMed ID: 11435077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
